Literature DB >> 19889793

Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.

Yoshiaki Kitamura1, Hiroyuki Kusuhara, Yuichi Sugiyama.   

Abstract

The intestine expresses metabolic enzymes and transporters and functions as a barrier to orally administered xenobiotics. This study aimed to examine the importance of multidrug resistance-associated protein 3 (Mrp3/Abcc3) in the serosal efflux of glucuronide conjugates formed in the intestine using wild-type and Mrp3(-/-) mice. The everted sacs of the intestine were incubated with 4-methylumbelliferone (4MU), and the efflux rates of intracellularly formed glucuronide conjugate of 4MU (4MUG) into the mucosal and serosal sides were determined. The permeability-surface area product across the serosal membrane (PS(serosal)) of 4MUG in wild-type mice was greatest in the duodenum followed by the jejunum, ileum, and colon. The corresponding parameters were significantly reduced in Mrp3(-/-) mice (approximately 33% of that in wild-type mice) except for the colon where the PS(serosal) of 4MUG was similar between wild-type and Mrp3(-/-) mice. There was no difference in the PS(mucosal) of 4MUG in whole segments of the intestine between wild-type and Mrp3(-/-) mice. In addition to 4MUG, the PS(serosal) of the glucuronide conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) and acetaminophen in the jejunal everted sacs were also significantly reduced in Mrp3(-/-) mice compared with wild-type mice. There was no difference in the mRNA and protein expression of efflux transporters between wild-type and Mrp3(-/-) mice. These results suggest that Mrp3 plays major roles in the efflux transport of various glucuronide conjugates from the enterocytes to the portal blood in the small intestine together with unknown transporter(s), but the contribution of Mrp3 to the basolateral efflux of 4MUG was negligible in the colon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889793     DOI: 10.1124/jpet.109.156943

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.

Authors:  Zhen Yang; Wei Zhu; Song Gao; Taijun Yin; Wen Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-06-26       Impact factor: 3.922

2.  Basolateral efflux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3) facilitates intestinal absorption of folates in mouse.

Authors:  Yoshiaki Kitamura; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2010-02-11       Impact factor: 4.200

3.  LOSS of Mrp1 alters detoxification enzyme expression in a tissue- and hormonal-status-specific manner.

Authors:  Jeffrey C Sivils; Tiffany M Ancrum; Lisa J Bain
Journal:  J Appl Toxicol       Date:  2012-04-23       Impact factor: 3.446

4.  Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.

Authors:  Yingjie Wei; Baojian Wu; Wen Jiang; Taijun Yin; Xiaobin Jia; Sumit Basu; Guangyi Yang; Ming Hu
Journal:  Mol Pharm       Date:  2013-04-23       Impact factor: 4.939

5.  Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.

Authors:  Shufan Ge; Taijun Yin; Beibei Xu; Song Gao; Ming Hu
Journal:  Pharm Res       Date:  2015-10-26       Impact factor: 4.200

6.  Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.

Authors:  Chuan Tian; Haifeng Ying; Rongyuan Zhuang; Xiaowei Zhang; Hongmin Lu; Hui Wang; Shuowen Wang; Qi Li; Chungang Wang; Xun Cai
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989

Review 7.  Enantioselective Drug Recognition by Drug Transporters.

Authors:  Yuichi Uwai
Journal:  Molecules       Date:  2018-11-22       Impact factor: 4.411

8.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.